V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough

Immunocore Holdings Executive Compensation (FY25)

IMCR · Executive and director compensation, fiscal 2025 only

The paid brief on Immunocore Holdings

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$1,500 for the Executive Compensation Report. Both reports for $2,400.
Data as of September 21, 2026Latest filing (8-K): May 27, 2026
4 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Immunocore Holdings brief$1,500Get the executive brief
118 figures on this page: 115 cited to the filing that reported them, 3 calculated from figures it prints. See the citations
Chief executive, fiscal 2025
◇
Bahija Jallal
Latest say-on-pay support
=
May 27, 2026
Chief executive pay ratio
◇
To the median employee

More on Immunocore Holdings

Five data products on this company. Each one is requested through the developer setup page.

Frequently asked questions

Answers drawn from the data on this page.
Who is Immunocore Holdings' chief executive and what were they paid?
Bahija Jallal was paid $10,885,268 in total compensation as Chief Executive Officer for fiscal 2025.
What was Immunocore Holdings' say-on-pay result?
For fiscal 2025, the say-on-pay proposal drew 77.5% support at the meeting held May 27, 2026.
Which companies are in Immunocore Holdings' peer group?
Companies named in the disclosed peer group include Amicus Therapeutics, Apellis Pharmaceuticals, Arcus Biosciences, Arrowhead Pharmaceuticals and Arvinas, among others.
What is Immunocore Holdings' chief executive pay ratio?
The company reported a chief executive pay ratio of 92:1 for fiscal 2025, against median employee compensation of $117,720.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Bahija Jallal
Chief Executive Officer
◇—◇◇◇—◇◇
Travis Coy
Chief Financial Officer and Head of Corporate Development
◇◇—◇◇—◇◇
David Berman
Former Executive Vice President, Head of Research & Development
Departed during or after this year
◇—◇◇◇—◇◇
Tina St. Leger
Chief Human Resources Officer
◇—◇◇◇—◇— not reconciled
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Bahija JallalOPTION◇——◇—◇◇
Bahija JallalRSU◇——◇——◇
David BermanRSU◇——◇——◇
David BermanOPTION◇——◇—◇◇
Tina St. LegerRSU◇——◇——◇
Tina St. LegerOPTION◇——◇—◇◇
Travis CoyOPTION◇——◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Bahija JallalOption◇—◇2/15/2033
RSU◇◇——
Option◇—◇2/15/2032
Option◇—◇2/15/2034
Option◇—◇2/16/2035
David BermanRSU◇◇——
Option◇—◇2/15/2032
Option◇—◇2/15/2033
Option◇—◇2/15/2034
Option◇—◇2/16/2035
Tina St. LegerRSU◇◇——
Option◇—◇3/31/2032
Option◇—◇2/15/2033
Option◇—◇2/15/2034
Option◇—◇2/16/2035
Travis CoyOption◇—◇12/31/2034
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Professor Sir John Bell
Board chair
◇—————◇
Siddharth Kaul
◇—————◇
Kristine Peterson
◇————◇◇
Roy S. Herbst
◇————◇◇
Professor Sir Peter Ratcliffe
◇—————◇
Ranjeev Krishana
◇—————◇
Robert Perez, William Pao, Travis Coy and Bahija Jallal served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Total board retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Options/Rsus.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Amicus Therapeutics FOLD
  • Apellis Pharmaceuticals APLS
  • Arcus Biosciences RCUS
  • Arrowhead Pharmaceuticals ARWR
  • Arvinas ARVN
  • Axsome Therapeutics AXSM
  • Beam Therapeutics BEAM
  • Bicycle Therapeutics BCYC
  • Galapagos NV symbol not shown
  • IDEAYA Biosciences IDYA
  • Immatics IMTX
  • Intra-Cellular Therapies ITCI
  • Ionis Pharmaceuticals IONS
  • Mirium Pharmaceuticals MIRM
  • Objectives symbol not shown
  • TG Therapeutics TGTX
  • Xencor XNCR

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025May 27, 2026=◇◇◇
2024May 15, 2025=◇◇◇
2023May 23, 2024=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Immunocore Holdings files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Immunocore Holdings disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Immunocore Holdings sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether Immunocore Holdings' disclosed peer group is defensible, who names Immunocore Holdings back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
118 figures on this page: 115 cited to the filing that reported them, 3 calculated from figures it prints.
115 cited to the filing
3 calculated from the filing

Documents cited

  1. 0001140361-26-022984
  2. 0001140361-26-015122
    CEO PAY RATIO · Director Compensation · Grants of Plan-Based Awards · M.D., P · and 2 more sections
  3. 0001140361-25-019282
  4. 0001140361-24-027312
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Immunocore Holdings executive compensation, FY2025.” https://intel.velarion.ai/comp/IMCR (accessed 2026).
Short form: data: Velarion

The paid brief for Immunocore Holdings

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$1,500 for the Executive Compensation Report. Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
4 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Immunocore Holdings and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Peers Immunocore Holdings discloses

The companies named in IMCR's own disclosed peer group.

Amicus TherapeuticsApellis PharmaceuticalsArcus BiosciencesArrowhead PharmaceuticalsArvinasAxsome TherapeuticsBeam TherapeuticsBicycle TherapeuticsIDEAYA BiosciencesIntra-Cellular TherapiesIonis PharmaceuticalsMirium PharmaceuticalsTG TherapeuticsXencor

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy